Cell-based therapy for chronic ischemic heart disease--a clinical perspective
Emerson C Perin1, Guilherme V Silva
1Stem Cell Center, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX, USA. eperin@bluegate.com
Cardiovascular Therapeutics
|October 20, 2010
Summary
Cardiovascular stem cell therapy using adult bone marrow cells is safe and feasible for chronic ischemic heart disease, showing modest functional improvements. Further phase 2 and 3 trials are needed to confirm these findings.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Background:
- Ischemic heart disease (IHD) affects millions globally, causing significant myocardial damage.
- Current treatments for IHD aim to restore blood flow and improve heart function.
- Cell therapy offers a promising regenerative approach for damaged heart muscle.
Purpose of the Study:
- To review major clinical studies on cardiovascular stem cell therapy in patients with chronic ischemic heart disease.
- To evaluate the safety, feasibility, and efficacy of current cell-based therapies for myocardial ischemia.
- To identify the most frequently used cell types and explore potential mechanisms of action.
Main Methods:
- Systematic review of clinical studies on cardiovascular stem cell therapy for chronic ischemic heart disease.
- Inclusion of all relevant studies due to the early stage of clinical investigation.
- Analysis of data on safety, functional status, quality of life, and underlying mechanisms.
Main Results:
- Adult cell-based therapy for chronic myocardial ischemia is safe and feasible.
- Initial trials with autologous bone marrow mononuclear cells show modest functional improvements.
- Potential benefits may involve multiple mechanisms, including paracrine effects.
Conclusions:
- Cardiovascular stem cell therapy is a safe and feasible option for patients with chronic ischemic heart disease.
- Early results suggest modest functional gains, warranting further investigation.
- Future phase 2 and 3 trials are essential to validate these findings and optimize therapeutic strategies.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...